Navigation Links
AstraZeneca's Partner, MAP Pharmaceuticals, Announces Phase 3 Study of Unit Dose Budesonide in Children with Asthma Did Not Meet Primary Endpoints
Date:2/23/2009

LONDON, Feb. 23 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. announced today that its initial Phase 3 clinical trial of Unit Dose Budesonide (UDB) for the potential treatment of children with asthma did not meet its co-primary endpoints: asthma control as assessed by changes from baseline in nighttime and daytime composite symptom scores, in either of the doses evaluated when compared with placebo.

AstraZeneca (NYSE: AZN) will work with MAP Pharmaceuticals to conduct further analyses of these data to determine appropriate next steps for the program.

AstraZeneca and MAP Pharmaceuticals have a collaboration agreement to develop and commercialize UDB.

About MAP Pharmaceuticals

MAP Pharmaceuticals is dedicated to developing and commercializing new therapies for children and adults suffering from chronic conditions that are not adequately treated by currently available medicines. The company has two product candidates in Phase 3 clinical development. Unit Dose Budesonide is being developed in collaboration with AstraZeneca for the potential treatment of asthma in children, and MAP0004 is being developed for the potential treatment of migraine. In addition, MAP Pharmaceuticals generates new pipeline opportunities by applying its proprietary drug particle and inhalation technologies to enhance the therapeutic benefits of proven drugs, while minimizing risk, by capitalizing on their known safety, efficacy and commercialization history.

Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com.

About AstraZeneca

AstraZeneca is a major international healthcare business engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and supplier for healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with healthcare sales of US$ 31.6 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines. For more information about AstraZeneca, please visit: www.astrazeneca.com


'/>"/>
SOURCE AstraZeneca
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Shareholder Class Action Filed Against Rigel Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
2. Inspiration Biopharmaceuticals, Inc. Initiates Phase 1 Clinical Trial of IB1001 for the Treatment of Hemophilia B
3. Jazz Pharmaceuticals, Inc. Completes Enrollment in Second of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
4. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
5. Lotus Pharmaceuticals, Inc.s New Drug Laevo-Bambutero Begins Evaluation for Clinical Trials
6. Jazz Pharmaceuticals, Inc. Announces Final Patient Has Completed Phase III Clinical Trial of Sodium Oxybate to Treat Fibromyalgia
7. Aegerion Pharmaceuticals, Inc. adds Peter Garrambone to Board of Directors, Secures Additional Capital for Clinical Trials
8. Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences
9. Meditrina Pharmaceuticals, Inc. Opens Investigational New Drug (IND) Application for Phase IIb Clinical Trial With MPI-676 in Endometriosis
10. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
11. Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytrens Contracture
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... 2017 AbbVie, a global biopharmaceutical company, today ... Julianne Hough is helping to raise awareness about ... about ME in EndoMEtriosis . "   The campaign, ... learn about and understand endometriosis, a disease affecting an ... address their symptoms with a healthcare professional.  Despite being ...
(Date:3/23/2017)... SANTA MONICA, Calif. , March 23, 2017 /PRNewswire/ ... the launch of a native mobile app for the ... the standard for surgery coordination and communication for physician ... of a native mobile app offers iPhone users even ... "Casetabs is making it even easier to connect ...
(Date:3/23/2017)... 2017 The global dermatology devices ... billion by 2025, according to a new report by Grand ... a faster rate due to rising concern amongst people regarding ... of esthetic procedures used for treating hair - and skin-related ... considered as the highest revenue generators for the market. ...
Breaking Medicine Technology:
(Date:3/23/2017)... ... March 23, 2017 , ... Michael Lanteri Agency, an ... Fort Collins area, has unveiled a collaboration with nonprofit Big Bones Canine Rescue ... this worthy cause may now be made at http://bigbonescaninerescue.com/ . , Big ...
(Date:3/23/2017)... , ... March 23, 2017 , ... After raising more ... FaceCradle , the most-funded travel pillow in crowdfunding history, has established a ... its wildly popular travel innovation to Americans. , “We’re excited to be operating on ...
(Date:3/23/2017)... ... ... feature 150+ Hospital and Health System Executive Speakers including: , , ... of the United States of America: George W. Bush , Boxing Legend, Successful ... Ray Leonard , JD, Chairperson, McGuireWoods LLP: Amber McGraw Walsh , ...
(Date:3/23/2017)... ... ... Sharon Kleyne, host of the nationally syndicated radio program, The Sharon Kleyne ... on her program about how she is looking forward to World Water Day on ... distinction. World Water Day, Kleyne pointed out, is an occasion for looking ahead with ...
(Date:3/23/2017)... ... 23, 2017 , ... Natural Subsistence, a company known for ... and nutrition, announced its product Leyzene is now available for purchase on Go4ItNutrition.com, ... that help people improve all aspects of their health so they can live ...
Breaking Medicine News(10 mins):